Fulcrum Therapeutics (FULC) Invested Capital (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Invested Capital data on file, last reported at $333.3 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $333.3 million, up 45.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $333.3 million (up 45.87% YoY), and the FY2025 annual result was $349.0 million, up 43.6% from the prior year.
• Invested Capital eased to $333.3 million in Q1 2026 per FULC's latest filing, from $349.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $349.0 million in Q4 2025 and troughed at $160.8 million in Q2 2022.
• A 5-year average of $243.8 million and a median of $235.2 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2024: Invested Capital soared 71.33% in 2023, then decreased 27.9% in 2024.
• A 5-year view of Invested Capital shows it stood at $198.9 million in 2022, then grew by 18.22% to $235.2 million in 2023, then advanced by 3.33% to $243.0 million in 2024, then soared by 43.6% to $349.0 million in 2025, then retreated by 4.5% to $333.3 million in 2026.
• Business Quant data shows FULC's Invested Capital at $333.3 million in Q1 2026, $349.0 million in Q4 2025, and $198.4 million in Q3 2025.